An Effective and Compliance Regimen of Paclitaxel Plus Cisplatin to Treat Metastatic Breast Cancer
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The primary endpoint of this phase II trial is the objective response rate of the stage I
(low-dose) regimen. The secondary endpoints include treatment-related toxicity, the change in
quality of life, progression free survival and overall survival. Simon's optimal two-stage
design will be used to determine the patient number.